Johnson & Johnson Launches Dual-Energy Cardiac Ablation Platform in Europe
Johnson & Johnson has announced the commercial launch of its Dual Energy THERMOCOOL SMARTTOUCH™ SF (DE STSF) Platform in Europe, expanding access to a catheter ablation solution that combines radiofrequency (RF) and pulsed field (PF) energy within a single system.
The platform integrates the Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter with the TRUPULSE™ Generator, enabling electrophysiologists to utilize both PF and RF energy during the same procedure. Designed to support personalized treatment strategies, the system offers flexibility across different workflows, cardiac anatomies, and ablation approaches.
Built on the established THERMOCOOL SMARTTOUCH™ SF platform, which has been used to treat more than one million patients worldwide, the solution combines a familiar point-by-point workflow with advanced dual-energy capabilities. The platform is integrated with the CARTO™ System, providing electro-anatomical mapping, catheter visualization, contact-force sensing, intracardiac ultrasound imaging, and PF/RF Index guidance to support procedural precision and workflow efficiency.
Clinical evidence supporting the platform includes 12-month results from the SmartfIRE first-in-human study, which demonstrated 86.9% effectiveness among patients treated with high adherence to the recommended workflow and PF/RF Index guidance. The study also reported meaningful improvements in quality of life, along with reductions in cardiovascular-related hospitalizations and antiarrhythmic drug use.
“DE STSF is a welcome addition to the EP lab because it allows physicians to incorporate new technology based on the gold RF standard smarttouch SF platform while maintaining familiar workflows with greater versatility by seamlessly switching between RF and PFA,” said Nicolas Derval1, M.D., Bordeaux, France. “This flexibility also provides greater ability to adjust treatment to different patient anatomies, clinical needs and procedural goals while increasing safety in ablating the posterior wall for example.”
“No two atrial fibrillation patients are the same, which is why personalized treatment and procedural versatility matter,” said Ricardo Martin, President EMEA, Electrophysiology, MedTech, Johnson & Johnson. “The launch of the Dual Energy THERMOCOOL SMARTTOUCH SF Platform reflects our continued commitment to providing physicians with a broad range of treatment options. As the latest addition to our integrated pulsed field ablation portfolio, it combines the familiarity of the world’s leading radiofrequency catheter with the versatility of pulsed field ablation, giving physicians greater confidence to tailor treatment to each patient’s needs.”
Clinical evidence supporting the platform includes 12-month results from the SmartfIRE first-in-human study, which demonstrated 86.9% effectiveness among patients treated with high adherence to the recommended workflow and PF/RF Index guidance. The study also reported meaningful improvements in quality of life, along with reductions in cardiovascular-related hospitalizations and antiarrhythmic drug use.
About Johnson & Johnson: Johnson & Johnson is a global healthcare company focused on developing innovative medicines and medical technologies. Through its MedTech business, the company provides solutions across cardiovascular care, surgery, orthopedics, vision, and electrophysiology, serving healthcare providers and patients worldwide.
Disclaimer
This article is an independent editorial summary based on publicly available information and company announcements. All trademarks, company names, and product names mentioned are the property of their respective owners.
